Merck & Co., known as MSD outside the United States and Canada, announced, that it is discontinuing development of nemtabrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor studied in chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and other hematologic malignancies.
The decision followed an external data monitoring committee review of the phase 3 BELLWAVE-011 trial, which suggested that the benefits of nemtabrutinib may not outweigh the risks in that study. Merck said its subsequent review of the full data supported the committee’s assessment and led the company to end the broader clinical development program.
What the BELLWAVE Review Found
The external committee’s assessment concerned the balance between benefit and risk within BELLWAVE-011. Merck did not identify the specific findings behind that assessment or say whether efficacy, safety, or a combination of the two drove it. The announcement did not provide numerical endpoint results, hazard ratios, p-values, or adverse event rates. It also did not describe how outcomes varied among participants or identify any patient subgroup discussed during the review.
Merck made the decision about the other phase 3 studies after reviewing the BELLWAVE-011 data in their entirety. The announcement reported no separate benefit-risk conclusions for BELLWAVE-008 or BELLWAVE-010. The company’s account therefore identifies the trial that prompted the decision while leaving the individual results from all three studies pending.
Marjorie Green, senior vice president and head of global oncology clinical development at Merck Research Laboratories said:
“Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical program.”
Green also thanked the patients, caregivers, and investigators who contributed to the studies.
Three Phase 3 Trials Included in the Decision
Merck named the following phase 3 trials in its November 17 announcement. The study identifiers correspond to the clinical trial registrations cited in the release.
- BELLWAVE-011 was the trial whose results the external data monitoring committee reviewed. Merck is discontinuing the study following the committee’s assessment and the company’s own analysis.
- BELLWAVE-008 was one of two additional phase 3 trials that Merck explicitly included in the decision to discontinue the wider program.
- BELLWAVE-010 the other phase 3 trial named in the announcement. The release did not specify separate findings for either of the two additional phase 3 studies.
Nemtabrutinib and the Wider Clinical Program
Nemtabrutinib, also known as MK-1026, is an investigational, oral, noncovalent BTK inhibitor. Merck described the drug as suppressing oncogenic B-cell receptor signaling. CLL and SLL were the two malignancies the company specifically named when describing the populations studied across the BELLWAVE program.
Beyond the three phase 3 trials, the release identified five other studies that evaluated nemtabrutinib. Four carried the BELLWAVE name, and the fifth was listed under the waveLINE name.
- BELLWAVE-001,
- BELLWAVE-003,
- BELLWAVE-015,
- BELLWAVE-027,
- waveLINE-006.
Merck listed those five studies as part of the drug’s clinical development history. The announcement did not give efficacy or safety results for them, describe their individual status at the time of the decision, or specify how the program closure would affect any remaining follow-up.
Communication With Trial Participants and Investigators
The company advised participants to speak with their study team and physician about what the discontinuation means for them, including their next steps and treatment options. The release did not outline a common transition schedule or provide trial-specific instructions about follow-up.
Analyses of the trial data are continuing, and Merck said it will share the results with the scientific community. The company did not specify a timeline or venue for that disclosure. Until those results are available, the public account of BELLWAVE-011 remains limited to the overall benefit-risk assessment, with the efficacy and safety findings that informed it still to be reported.
You can also read: BTK Inhibitors in Chronic Lymphocytic Leukemia: Current Practice and Future Perspectives.
